Purpose: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab: Avastin(R)) has become one of the chief choices for the treatment of macular edema and neovascular age-related macular degeneration. However, the effect of blocking the VEGF function has not been thoroughly explored in vivo. A previous study has reported that intravitreal injection of bevacizumab had no retinal toxicity on rats; however, bevacizumab is human-specific and does not react with rat VEGF. In this study, we examined the effect of anti-rat VEGF antibody and bevacizumab on rat retina in vivo and in vitro, especially focusing on retinal ganglion cells (RGCs).
Methods: In vitro, rat RGCs were purified by a two-step immunopanning procedure, and incubated in the presence of VEGF, bevacizumab, anti-rat VEGF antibody, and control-IgG for three days. The number of viable RGCs was counted. In vivo, after intravitreal injections of bevacizumab, anti-rat VEGF antibody, and control-IgG, viable RGCs were visualized by retrolabeling with Fluo-gold and enumerated to examine the toxicity.
Results: In vivo, the number of viable RGCs in the VEGF-treated group (0.99±0.29 vs control), the bevacizumab-treated group (1.0±0.23 vs control), the anti-rat VEGF antibody-treated group (0.98±0.18 vs control) and the control IgG-treated group (0.98±0.19 vs control) was not statistically different from that of the control group after 3 days. In vitro, the number of viable RGCs in the bevacizumab-treated group (2613±230/mm2), the anti-rat VEGF antibody-treated group (2600 ±140/mm2) and the control IgG-treated group (2656 ±150/mm2) was not statistically different from that of the control group (2656±150/mm2) after 7days. There were no apparent histological abnormalities.
Conclusion: This study suggests that bevacizumab and anti-rat VEGF antibody have no short-term, direct retinal toxicity using the rat model. Intravitreal injection of bevacizumab shows no short-term, direct toxicity on RGCs.
- retinal ganglion cells